FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376642802> ?p ?o ?g. }

• W4376642802 endingPage "e2313667" @default.
• W4376642802 startingPage "e2313667" @default.
• W4376642802 abstract "Importance The antiandrogenic effect of the 5α-reductase inhibitor (5-ARI) has been investigated for its role in preventing male-predominant cancers. Although 5-ARI has been widely associated with prostate cancer, its association with urothelial bladder cancer (BC), another cancer experienced predominantly by males, has been less explored. Objective To assess the association between 5-ARI prescription prior to BC diagnosis and reduced risk of BC progression. Design, Setting, and Participants This cohort study analyzed patient claims data from the Korean National Health Insurance Service database. The nationwide cohort included all male patients with BC diagnosis in this database from January 1, 2008, to December 31, 2019. Propensity score matching was conducted to balance the covariates between 2 treatment groups: α-blocker only group and 5-ARI plus α-blocker group. Data were analyzed from April 2021 to March 2023. Exposure Newly dispensed prescriptions of 5-ARIs at least 12 months prior to cohort entry (BC diagnosis), with a minimum of 2 prescriptions filled. Main Outcomes and Measures The primary outcomes were the risks of bladder instillation and radical cystectomy, and the secondary outcome was all-cause mortality. To compare the risk of outcomes, the hazard ratio (HR) was estimated using a Cox proportional hazards regression model and difference in restricted mean survival time analysis. Results The study cohort initially included 22 845 males with BC. After propensity score matching, 5300 patients each were assigned to the α-blocker only group (mean [SD] age, 68.3 [8.8] years) and 5-ARI plus α-blocker group (mean [SD] age, 67.8 [8.6] years). Compared with the α-blocker only group, the 5-ARI plus α-blocker group had a lower risk of mortality (adjusted HR [AHR], 0.83; 95% CI, 0.75-0.91), bladder instillation (crude HR, 0.84; 95% CI, 0.77-0.92), and radical cystectomy (AHR, 0.74; 95% CI, 0.62-0.88). The differences in restricted mean survival time were 92.6 (95% CI, 25.7-159.4) days for all-cause mortality, 88.1 (95% CI, 25.2-150.9) days for bladder instillation, and 68.0 (95% CI, 31.6-104.3) days for radical cystectomy. The incidence rates per 1000 person-years were 85.59 (95% CI, 80.53-90.88) for bladder instillation and 19.57 (95% CI, 17.41-21.91) for radical cystectomy in the α-blocker only group and 66.43 (95% CI, 62.22-70.84) for bladder instillation and 13.56 (95% CI, 11.86-15.45) for radical cystectomy in the 5-ARI plus α-blocker group. Conclusions and relevance Results of this study suggest an association between prediagnostic prescription of 5-ARI and reduced risk of BC progression." @default.
• W4376642802 created "2023-05-17" @default.
• W4376642802 creator A5029761730 @default.
• W4376642802 creator A5032707769 @default.
• W4376642802 creator A5037316372 @default.
• W4376642802 creator A5040944986 @default.
• W4376642802 creator A5054993337 @default.
• W4376642802 creator A5066482871 @default.
• W4376642802 creator A5066566375 @default.
• W4376642802 creator A5070859865 @default.
• W4376642802 creator A5073130641 @default.
• W4376642802 creator A5074039379 @default.
• W4376642802 creator A5075651504 @default.
• W4376642802 date "2023-05-16" @default.
• W4376642802 modified "2023-10-01" @default.
• W4376642802 title "Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea" @default.
• W4376642802 cites W1491207647 @default.
• W4376642802 cites W1594826301 @default.
• W4376642802 cites W1598862994 @default.
• W4376642802 cites W1757407923 @default.
• W4376642802 cites W1964098393 @default.
• W4376642802 cites W1977247044 @default.
• W4376642802 cites W1993118867 @default.
• W4376642802 cites W2020095621 @default.
• W4376642802 cites W2035404753 @default.
• W4376642802 cites W2053766817 @default.
• W4376642802 cites W2057610488 @default.
• W4376642802 cites W2059796825 @default.
• W4376642802 cites W2093252458 @default.
• W4376642802 cites W2118264281 @default.
• W4376642802 cites W2134555283 @default.
• W4376642802 cites W2151043608 @default.
• W4376642802 cites W2164960433 @default.
• W4376642802 cites W2172164477 @default.
• W4376642802 cites W2224079506 @default.
• W4376642802 cites W2237313791 @default.
• W4376642802 cites W2411898115 @default.
• W4376642802 cites W2503810307 @default.
• W4376642802 cites W2534750020 @default.
• W4376642802 cites W2575790444 @default.
• W4376642802 cites W2589780548 @default.
• W4376642802 cites W2599017172 @default.
• W4376642802 cites W2800291589 @default.
• W4376642802 cites W2883706387 @default.
• W4376642802 cites W2904964912 @default.
• W4376642802 cites W2941544942 @default.
• W4376642802 cites W2944049715 @default.
• W4376642802 cites W2980608465 @default.
• W4376642802 cites W2981231056 @default.
• W4376642802 cites W2999253935 @default.
• W4376642802 cites W3013480745 @default.
• W4376642802 cites W3023288864 @default.
• W4376642802 cites W3034102609 @default.
• W4376642802 cites W3081137277 @default.
• W4376642802 cites W3091856456 @default.
• W4376642802 cites W3102493364 @default.
• W4376642802 cites W3135529189 @default.
• W4376642802 cites W3158323486 @default.
• W4376642802 cites W3169072539 @default.
• W4376642802 cites W3198719997 @default.
• W4376642802 cites W4213172209 @default.
• W4376642802 cites W4249863806 @default.
• W4376642802 cites W4255412331 @default.
• W4376642802 cites W4280565236 @default.
• W4376642802 cites W4285530885 @default.
• W4376642802 cites W4293410833 @default.
• W4376642802 cites W4362207783 @default.
• W4376642802 doi "https://doi.org/10.1001/jamanetworkopen.2023.13667" @default.
• W4376642802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37191958" @default.
• W4376642802 hasPublicationYear "2023" @default.
• W4376642802 type Work @default.
• W4376642802 citedByCount "1" @default.
• W4376642802 countsByYear W43766428022023 @default.
• W4376642802 crossrefType "journal-article" @default.
• W4376642802 hasAuthorship W4376642802A5029761730 @default.
• W4376642802 hasAuthorship W4376642802A5032707769 @default.
• W4376642802 hasAuthorship W4376642802A5037316372 @default.
• W4376642802 hasAuthorship W4376642802A5040944986 @default.
• W4376642802 hasAuthorship W4376642802A5054993337 @default.
• W4376642802 hasAuthorship W4376642802A5066482871 @default.
• W4376642802 hasAuthorship W4376642802A5066566375 @default.
• W4376642802 hasAuthorship W4376642802A5070859865 @default.
• W4376642802 hasAuthorship W4376642802A5073130641 @default.
• W4376642802 hasAuthorship W4376642802A5074039379 @default.
• W4376642802 hasAuthorship W4376642802A5075651504 @default.
• W4376642802 hasBestOaLocation W43766428021 @default.
• W4376642802 hasConcept C121608353 @default.
• W4376642802 hasConcept C126322002 @default.
• W4376642802 hasConcept C167135981 @default.
• W4376642802 hasConcept C17923572 @default.
• W4376642802 hasConcept C201903717 @default.
• W4376642802 hasConcept C207103383 @default.
• W4376642802 hasConcept C2426938 @default.
• W4376642802 hasConcept C2775910329 @default.
• W4376642802 hasConcept C2778527826 @default.
• W4376642802 hasConcept C2780192828 @default.
• W4376642802 hasConcept C2780352672 @default.
• W4376642802 hasConcept C29456083 @default.

• next